These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 12097265)

  • 1. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
    Zeng G; Li Y; El-Gamil M; Sidney J; Sette A; Wang RF; Rosenberg SA; Robbins PF
    Cancer Res; 2002 Jul; 62(13):3630-5. PubMed ID: 12097265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
    Khong HT; Yang JC; Topalian SL; Sherry RM; Mavroukakis SA; White DE; Rosenberg SA
    J Immunother; 2004; 27(6):472-7. PubMed ID: 15534491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
    Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
    Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
    Bownds S; Tong-On P; Rosenberg SA; Parkhurst M
    J Immunother; 2001; 24(1):1-9. PubMed ID: 11211143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
    Zeng G; Touloukian CE; Wang X; Restifo NP; Rosenberg SA; Wang RF
    J Immunol; 2000 Jul; 165(2):1153-9. PubMed ID: 10878395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
    Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
    J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
    Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
    Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
    Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.